Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | ELOVL6 | Q9H5J4 | 2/20 | 0.42 |
| ▸ | ELOVL3 | Q9HB03 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018805 | 0.94 | NAMPT (0.53) | NAMPTTRPM8PAX8TRPV1ELOVL6 | |
| SCHEMBL3026582 | 0.89 | TRPM8 (0.44) | NAMPTTRPM8PAX8 | |
| SCHEMBL3025448 | 0.84 | ELOVL6 (0.43) | TRPM8ELOVL6 | |
| SCHEMBL3022138 | 0.83 | NPY5R (0.45) | TRPM8 | |
| SCHEMBL3020628 | 0.83 | TRPM8 (0.44) | TRPM8PAX8 | |
| SCHEMBL3018503 | 0.82 | OPRD1 (0.47) | — | |
| SCHEMBL3006374 | 0.78 | TRPM8 (0.46) | TRPM8PAX8 | |
| SCHEMBL3012867 | 0.77 | NPY5R (0.49) | NAMPT | |
| SCHEMBL3022934 | 0.76 | CFTR (0.44) | TRPM8 | |
| SCHEMBL4751235 | 0.76 | GRIN2B (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS R & D LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | SCN1B, SCN2B, SCN1A | NAMPT 1805/4885TRPM8 238/4885PAX8 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.